Oxyresveratrol
CAS No. 29700-22-9
Oxyresveratrol ( trans-Oxyresveratrol )
Catalog No. M18383 CAS No. 29700-22-9
Oxyresveratro is useful to trauma models, as toxicity to glia could be beneficial by inhibiting reactive gliosis.
Purity : 98%
Size | Price / USD | Stock | Quantity |
50MG | 27 | In Stock |
|
100MG | 41 | In Stock |
|
500MG | 138 | In Stock |
|
1G | 221 | In Stock |
|
Biological Information
-
Product NameOxyresveratrol
-
NoteResearch use only, not for human use.
-
Brief DescriptionOxyresveratro is useful to trauma models, as toxicity to glia could be beneficial by inhibiting reactive gliosis.
-
DescriptionOxyresveratro can inhibit tyrosinase activity. Oxyresveratro is useful to trauma models, as toxicity to glia could be beneficial by inhibiting reactive gliosis. Oxyresveratrol has antioxidant activity, can reduce neuronal oxidative damage and protect hepatocytes against oxidative stress and mitochondrial dysfunction, which may be associated with activation of Nrf2.
-
Synonymstrans-Oxyresveratrol
-
PathwayOthers
-
TargetOther Targets
-
RecptorTyrosinase
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number29700-22-9
-
Formula Weight244.24
-
Molecular FormulaC14H12O4
-
Purity98%
-
SolubilityDMSO : ≥ 34 mg/mL; 139.21 mM
-
SMILESC1=CC(=C(C=C1O)O)C=CC2=CC(=CC(=C2)O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
3-Methylhistamine di...
N tau-methylhistamine is one of the histamine metabolites. N tau-methylhistamine in plasma and urine is a good parameter for histamine release and the determination of this histamine metabolite is generally less hampered by possible artifacts (due to basophil disrupture a very short half-life time or bacterial production) than determinations of histamine itself.
-
SC-26196
SC-26196 is an orally active inhibitor of Delta6 desaturase (D6D) with IC50 of 0.2 μM in a rat liver microsomal assay, with antiinflammatory properties.
-
hSMG-1 inhibitor 11e
hSMG-1 inhibitor 11e is a potent and selective hSMG-1 kinase inhibitor with an IC50 of 900-fold selectivity over mTOR (IC50 of 45 nM), PI3Kα/γ (IC50s of 61 nM and 92 nM) and CDK1/CDK2 (IC50s of 32 μM and 7.1 μM).